Literature DB >> 20432463

Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.

Liaquat Suleman Verjee1, Kim Midwood, Dominique Davidson, Mark Eastwood, Jagdeep Nanchahal.   

Abstract

The objective was to study Dupuytren's myofibroblast cells in constrained collagen matrices in order to more closely emulate their in vivo environment and, to correlate their contractility with alpha-smooth muscle actin (alpha-SMA) expression and determine if dermal fibroblasts regulate Dupuytren's myofibroblast phenotype. Isotonic and isometric force contraction by cells isolated from Dupuytren's nodules, palmar and non-palmar skin fibroblasts was measured in collagen matrices. The effect of co-culturing nodule cells with dermal fibroblasts on isometric contraction was examined. Isometric contraction was correlated with levels of alpha-SMA mRNA by pcr and protein by Western blotting, and alpha-SMA distribution assessed by immunofluorescence. Dupuytren's nodule cells exhibited similar levels of isotonic contraction to both palmar and non-palmar dermal fibroblasts. However, nodule cells generated high levels of isometric force (mean: 3.5 dynes/h), which continued to increase over 24 h to a maximum of 173 dynes. In contrast, dermal fibroblasts initially exhibited low levels of contraction (mean: 0.5 dynes/h) and reached tensional homeostasis on average after 15 h (range: 4-20 h), with a maximum force of 52 dynes. Although all three cell types had similar alpha-SMA mRNA levels, increased levels of alpha-SMA protein were observed in nodule cells compared to dermal fibroblasts. alpha-SMA localised to stress fibres in 35% (range: 26-50%) of nodule cells compared to only 3% (range:0-6%) of dermal fibroblasts. Co-cultures of Dupuytren's cells and dermal fibroblasts showed no contractile differences. The contractile phenotype of Dupuytren's myofibroblasts is determined by increased alpha-SMA protein distributed in stress fibres, not by cellular mRNA levels. Dupuytren's cell contractility is not influenced by dermal fibroblasts. (c) 2010 Wiley-Liss, Inc.

Mesh:

Substances:

Year:  2010        PMID: 20432463     DOI: 10.1002/jcp.22167

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  Human Dupuytren's Ex Vivo Culture for the Study of Myofibroblasts and Extracellular Matrix Interactions.

Authors:  Sofia Karkampouna; Peter Kloen; Miryam C Obdeijn; Scott M Riester; Andre J van Wijnen; Marianna Kruithof-de Julio
Journal:  J Vis Exp       Date:  2015-04-18       Impact factor: 1.355

2.  Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture.

Authors:  Latha Satish; David B O'Gorman; Sandra Johnson; Christina Raykha; Bing Siang Gan; James H-C Wang; Sandeep Kathju
Journal:  Cell Stress Chaperones       Date:  2013-01-06       Impact factor: 3.667

3.  Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.

Authors:  Liaquat S Verjee; Jennifer S N Verhoekx; James K K Chan; Thomas Krausgruber; Vicky Nicolaidou; David Izadi; Dominique Davidson; Marc Feldmann; Kim S Midwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

4.  Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.

Authors:  Syed Amir Iqbal; Christopher Manning; Farhatullah Syed; Venkatesh Kolluru; Mike Hayton; Stewart Watson; Ardeshir Bayat
Journal:  Stem Cells Dev       Date:  2011-07-19       Impact factor: 3.272

5.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

6.  Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.

Authors:  Theerut Luangmonkong; Su Suriguga; Emilia Bigaeva; Miriam Boersema; Dorenda Oosterhuis; Koert P de Jong; Detlef Schuppan; Henricus A M Mutsaers; Peter Olinga
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 7.  Anti-TNF therapy: past, present and future.

Authors:  Claudia Monaco; Jagdeep Nanchahal; Peter Taylor; Marc Feldmann
Journal:  Int Immunol       Date:  2014-11-19       Impact factor: 4.823

8.  Chaperonin containing T-complex polypeptide subunit eta is a potential marker of joint contracture: an experimental study in the rat.

Authors:  Ronghan He; Zhe Wang; Yunxiang Lu; Junqi Huang; Jianhua Ren; Kun Wang
Journal:  Cell Stress Chaperones       Date:  2015-07-30       Impact factor: 3.667

9.  In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties.

Authors:  Farhatullah Syed; Alexis N Thomas; Subir Singh; Venkatesh Kolluru; Susan G Emeigh Hart; Ardeshir Bayat
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

10.  Skin, fascias, and scars: symptoms and systemic connections.

Authors:  Bruno Bordoni; Emiliano Zanier
Journal:  J Multidiscip Healthc       Date:  2013-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.